Celsion to Present New Data from OVATION Trial at Ovarian Cancer Meeting

Celsion to Present New Data from OVATION Trial at Ovarian Cancer Meeting
All newly diagnosed ovarian cancer patients enrolled in the OVATION Phase 1b trial (NCT02480374) to date benefited from the addition of GEN-1 to standard of care, according to Celsion, the drug’s developer. The new data, accepted for presentation at the American Association for Cancer Research (AACR) Addressing Critical Questions in Ovarian Cancer Research and Treatment Special Conference, Oct.

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *